. 1 .

TO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3211.1013-001		LICATION NO. 799,389	
in an application	FIRST NAMED INVENTOR Mitsunori Ono		FILING DATE March 12, 2	2004
November 11, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 1892	RMATION NO.	GROUP 1614

U.S. PATENT DOCUMENTS								
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT				
KN	AA	6,214,855 B1	04/10/2001	Gemba, et al.				
KY	AB	6,362,191 B1	03/26/2002	Mills				
KN	AC	US2003/0153759 A1	08/14/2003	Koya, et al.				
KN	AD	US2004/0152897 A1	08/05/2004	Sun, et al.				
	AE							
	AF							
	AG							
	АН							
	ΑI							
	Į,							
	AK							
	AA2							
	AB2							
	AC2							
	AD2							
	AE2							
	AF2							
	AG2							
	AH2							
	AI2							
	AJ2							
	AK2							
	AA3							
	AB3							
	AC3							

11 11	
EXAMINER # M/h	DATE CONSIDERED $8/30/2006$

DTO	1440	REPRO	DITCED
PILX-	1447	KEPKU	DUCEL

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

November 11, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPI	LICATION NO.
3211.1013-001	10/	799,389

FIRST NAMED INVENTOR
Mitsunori Ono

FILING DATE
March 12, 2004

EXAMINER
Not yet assigned

CONFIRMATION NO. 1892

GROUP 1614

		F	OREIGN PATENT DO	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS YES	SLATION NO
KH	AL	GB 2287706 A	09/27/1995	Fujisawa Pharmaceutical Co., Ltd.		
	AM	WO 99/59999	11/25/1999	Adachi Makato, et al.		
	AN	WO 00/21563	04/20/2000	Shionogi & Co., Ltd., et al.		
. \	AO	EP 1 085 021 A1	03/21/2001	Shionogi & Co., Ltd.		
	AP	EP 1 157 704 A1	11/28/2001	Shionogi & Co., Ltd.		
	AQ	WO 96/03383 A1	02/08/1996	Eli Lilly and Company, et al.		
1	AL2	WO 98/47507	10/29/1998	Shionogi & Co., Ltd.		
	AM2	WO 99/24033	05/20/1999	Shionogi & Co., Ltd., et al.		
J	AN2	WO 99/51605	10/14/1999	Shionogi & Co., Ltd.		
	AO2					
	AP2		N			
	AQ2					
	AL3					
-	АМ3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					,

EXAMINER	DATE CONSIDERED	8/30/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 10/799,389			_
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Mitsunori Ono		FILING DATE March 12, 2	2004
November 11, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONF 1892	IRMATION NO.	GROUP 1614

		<del></del>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
K	K	AR	Doherty, A.M., "Phosphodiesterase 4 Inhibitors as Novel Anti-Inflammatory Agents," Current Opinion in Chemical Biology 3: 466-473 (1999).	
	AS Mann, D.L., "Inflammatory Mediators and the Failing Heart," Circ Res 91: 988-998 (2002).			
1		AT	Newton, et al., "Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-α," J Med Chem 42(13): 2295-2314 (1999).	
		AU	Roitt, I., et al., "Turnour Immunology." In Immunology, 3rd ed., (London: Mosby), pp. 17.1-17.12 (1993).	
		AV	Tenor, et al., "Cyclic Nucleotide Phosphodiesterase Isoenzyme Activities in Human Alveolar Macrophages," Clin Exp Allergy, 25(7): 625-633 (1995).	
		AW	Copar, A., et al., "A New Approach for the Synthesis of Fused Pyrroles: The Synthesis of Acyl Substituted Pyrrolo[1,2-x]azines," J. Heterocyclic Chem. 30: 1577-1579 (1993).	
		AX		
		AY		
:		AZ		
		AR2		
		AS2		
		AT2		
		AU2		
		AV2		
		AW2	·	

		11	
EXAMINER	f my	h DA	ATE CONSIDERED 8/30/2006

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;513224;1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3211.1013-001		LICATION NO. 1799,389	
SUPPLEMENTAL INFORMATION  OF E  OF E	FIRST NAMED INVENTOR Mitsunori Ono  FILING DATE March 12, 2		2004	
December 2, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONF 1892	IRMATION NO.	GROUP 1614

CW7 a TH	DEW.			
ļ		U.S	S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
KM	AE	6,472,389 B1	10/29/2002	Ohtani, et al.
	AF			
	AG			
	АН			
	AI		·	
	LA			
	AK			
	AA2		·	
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
<u> </u>	AB3			
	AC3			

EXAMINER DATE CONSIDERED 8/30/2006		-11	
	EXAMINER	If Milh	